Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
CNOOC
00883
CA Stock MarketDetailed Quotes
Medicenna Therapeutics Corp (MDNA)
- 0.610
- +0.020+3.39%
15min DelayMarket Closed May 1 16:00 ET
50.89MMarket Cap-4.07P/E (TTM)
0.630High0.590Low126.15KVolume0.630Open0.590Prev Close75.81KTurnover1.97052wk High0.19%Turnover Ratio83.42MShares0.54052wk Low-0.15EPS TTM40.23MFloat Cap7.250Historical HighLossP/E (Static)65.95MShs Float0.215Historical Low-0.15EPS LYR6.78%Range %--Dividend TTM8.13P/B1Lot Size--Div Yield TTM
Medicenna Therapeutics Corp (MDNA) Cash Flow
Quarterly+Annual
YOY
| (Q3)Dec 31, 2025 | (Q2)Sep 30, 2025 | (Q1)Jun 30, 2025 | (FY)Mar 31, 2025 | (Q4)Mar 31, 2025 | (Q3)Dec 31, 2024 | (Q2)Sep 30, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -39.66%-4.97M | 12.04%-4.94M | -52.32%-3.55M | -1.43%-16.49M | -3.12%-5M | 11.70%-3.56M | -43.15%-5.61M | 32.87%-2.33M | -28.47%-16.26M | -111.48%-4.85M |
| Net income from continuing operations | 15.93%-4.36M | -17.27%-4.88M | -35.50%-4.93M | 53.64%-11.81M | 108.54%1.19M | -4.30%-5.19M | -11.85%-4.16M | -27.08%-3.64M | -153.44%-25.47M | -260.58%-13.9M |
| Operating gains losses | -353.45%-1.14M | 56.49%-429K | -423.61%-377K | -188.04%-7.25M | -164.01%-6.64M | 515.07%449K | -2.71%-986K | 94.26%-72K | 257.48%8.24M | 647.08%10.38M |
| Depreciation and amortization | -11.11%16K | 109.09%23K | 280.00%19K | 1,225.00%53K | 1,800.00%19K | 1,700.00%18K | 1,000.00%11K | 400.00%5K | 0.00%4K | 0.00%1K |
| Remuneration paid in stock | -47.38%331K | -28.66%468K | -9.93%390K | 83.13%2.21M | 1.85%496K | 295.60%629K | 145.69%656K | 46.28%433K | -11.82%1.21M | 151.03%487K |
| Other non cashItems | --5K | --6K | --7K | -3.35%-1.02M | ---1.02M | --0 | ---- | ---- | 15.46%-984K | ---- |
| Change In working capital | -65.74%185K | 89.22%-122K | 42.42%1.34M | 77.33%1.31M | 217.15%963K | -24.79%540K | -343.44%-1.13M | 148.16%943K | -69.25%741K | -180.35%-822K |
| -Change in receivables | -173.33%-176K | -108.62%-5K | 657.34%1.22M | -112.46%-209K | -185.00%-289K | -56.04%240K | 137.42%58K | -123.02%-218K | 36.31%1.68M | 60.38%340K |
| -Change in payables and accrued expense | 20.33%361K | 90.17%-117K | -88.98%128K | 262.54%1.52M | 207.75%1.25M | 74.42%300K | -291.94%-1.19M | 304.76%1.16M | -179.47%-937K | -243.28%-1.16M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -39.66%-4.97M | 12.04%-4.94M | -52.32%-3.55M | -1.43%-16.49M | -3.12%-5M | 11.70%-3.56M | -43.15%-5.61M | 32.87%-2.33M | -28.47%-16.26M | -111.48%-4.85M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 2K | 0 | 0 | -33K | 0 | 0 | -2K | -31K | 0 | 0 |
| Net PPE purchase and sale | --2K | --0 | --0 | ---33K | --0 | --0 | ---2K | ---31K | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --2K | --0 | --0 | ---33K | --0 | --0 | ---2K | ---31K | --0 | --0 |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -101.00%-19K | -102.69%-19K | -99.81%39K | 23.49M | -19K | 1.91M | 706K | 20.9M | 0 | 0 |
| Net issuance payments of debt | ---19K | ---19K | ---13K | ---19K | ---19K | --0 | --0 | --0 | --0 | ---- |
| Net common stock issuance | --0 | --0 | --0 | --19.71M | --0 | --0 | --0 | --19.71M | --0 | --0 |
| Proceeds from stock option exercised by employees | --0 | --0 | -95.60%52K | --3.8M | --0 | --1.91M | --706K | --1.18M | --0 | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -101.00%-19K | -102.69%-19K | -99.81%39K | --23.49M | ---19K | --1.91M | --706K | --20.9M | --0 | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -48.24%15.75M | -42.58%20.46M | 46.25%24.84M | -49.45%16.98M | 37.86%30M | 18.45%30.43M | 20.31%35.63M | -49.45%16.98M | 63.60%33.6M | -39.82%21.76M |
| Current changes in cash | -202.49%-4.98M | -0.96%-4.96M | -118.92%-3.51M | 142.85%6.97M | -3.51%-5.02M | 59.09%-1.65M | -25.20%-4.91M | 634.54%18.54M | -234.35%-16.26M | -95.36%-4.85M |
| Effect of exchange rate changes | -112.49%-152K | 183.33%245K | -899.08%-871K | 350.85%888K | -308.70%-144K | 1,154.64%1.22M | -4,100.00%-294K | 121.25%109K | -136.95%-354K | 189.61%69K |
| End cash Position | -64.62%10.61M | -48.24%15.75M | -42.58%20.46M | 46.25%24.84M | 46.25%24.84M | 37.86%30M | 18.45%30.43M | 20.31%35.63M | -49.45%16.98M | -49.45%16.98M |
| Free cash from | -39.66%-4.97M | 12.07%-4.94M | -50.32%-3.55M | -1.63%-16.53M | -3.12%-5M | 11.70%-3.56M | -43.20%-5.62M | 31.98%-2.36M | -28.47%-16.26M | -111.48%-4.85M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
On May 1, the more than two-month-long military conflict involving the US, Israel, and Iran will reach a legal milestone, potentially increa
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm